Skip to main content


Acute Lymphoblastic Leukemia

An economic model estimated the total costs associated with tisagenlecleucel treatment for pediatric and young adult…
Use of minimal residual disease assessment is increasing in the routine management of patients with B-cell ALL and…

(Changes "anemia" to "leukemia" in para 1.)

By Marilynn Larkin

NEW YORK (Reuters Health) - Acute lymphoblastic leukemia (ALL) is more likely to relapse in adolescents and young…

By Marilynn Larkin

NEW YORK (Reuters Health) - Acute lymphoblastic anemia (ALL) is more likely to relapse in adolescents and young adults (AYAs; ages 15-39) than in children, and lower…

Researchers from a large health care system implemented a multifaceted program that improved the uptake of NCCN…
A review published in JAMA Oncology sheds light on the importance of therapies targeting specific transcripts or…
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus…
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas…
Risk algorithms for pediatric patients with acute lymphoblastic leukemia should incorporate genetics with minimal…
The NCCN has released an updated guideline for the treatment of various types of ALL to include a recently approved…
Back to Top